DM4
DM4 is a maytansinoid payload released in a form that can cross membranes, giving mirvetuximab soravtansine a bystander effect that DM1 lacks.
DM4 (ravtansine or soravtansine) is attached through a hindered disulfide linker (sulfo-SPDB). After cleavage the payload is S-methylated inside the cell into a neutral, permeable form, so it can diffuse into neighbouring cells. Ocular toxicity (keratopathy, blurred vision) is the dose-limiting effect and is managed with steroid eye drops.
Pages like this
not linked directly; found by shared links- TermDM1
Shares Bystander effect (ADC), Tubulin inhibitor payloads, Mitosis & the spindle assembly checkpoint, Payload (ADC).
- TermMMAF
Shares Bystander effect (ADC), Tubulin inhibitor payloads, Payload (ADC), Antibody-drug conjugate (ADC).
- TermMMAE
Shares Bystander effect (ADC), Tubulin inhibitor payloads, Mitosis & the spindle assembly checkpoint, Payload (ADC).
- IdeaTumour-on-a-chip with blood flow to test whether big drugs actually get in
Shares Bystander effect (ADC), Payload (ADC), Antibody-drug conjugate (ADC).
- IdeaDose and schedule optimisation trials specific to antibody-drug conjugates
Shares Mirvetuximab soravtansine, Payload (ADC), Antibody-drug conjugate (ADC).
- IdeaUse antibodies to deliver protein-destroying drugs into the right cells
Shares Bystander effect (ADC), Payload (ADC), Antibody-drug conjugate (ADC).
- ProductEribulin
Shares Mitosis & the spindle assembly checkpoint, Payload (ADC).
- TermDuocarmycin (seco-DUBA)